Louisiana State Employees Retirement System Takes Position in Repligen Corporation $RGEN

Louisiana State Employees Retirement System purchased a new position in Repligen Corporation (NASDAQ:RGEN) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 15,300 shares of the biotechnology company’s stock, valued at approximately $1,803,000.

Other institutional investors have also made changes to their positions in the company. Bayforest Capital Ltd acquired a new position in shares of Repligen during the 4th quarter worth about $32,000. Rachor Investment Advisory Services LLC acquired a new stake in shares of Repligen in the 4th quarter valued at approximately $33,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen in the 3rd quarter valued at approximately $29,000. Los Angeles Capital Management LLC bought a new position in Repligen during the 4th quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC boosted its stake in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have weighed in on RGEN. JPMorgan Chase & Co. cut their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Royal Bank Of Canada began coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target for the company. HC Wainwright upped their price objective on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Rothschild & Co Redburn set a $160.00 price objective on Repligen and gave the stock a “buy” rating in a research note on Friday, April 17th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $142.00 target price on shares of Repligen in a research note on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $164.64.

Repligen Stock Down 0.4%

Repligen stock opened at $136.44 on Wednesday. The company has a 50 day moving average of $123.14 and a 200-day moving average of $135.00. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The stock has a market capitalization of $7.70 billion, a PE ratio of 151.60, a price-to-earnings-growth ratio of 2.64 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. The business had revenue of $194.25 million for the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The firm’s revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities research analysts anticipate that Repligen Corporation will post 1.99 EPS for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.